Rhythm Biosciences Limited, a medical diagnostics technology company, engages in developing and commercializing medical diagnostics technology in Australia and internationally.
Excellent balance sheet with weak fundamentals.
Share Price & News
How has Rhythm Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RHY's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: RHY underperformed the Australian Healthcare industry which returned -1.9% over the past year.
Return vs Market: RHY underperformed the Australian Market which returned -11.2% over the past year.
Price Volatility Vs. Market
How volatile is Rhythm Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StIs Rhythm Biosciences (ASX:RHY) In A Good Position To Invest In Growth?
1 month ago | Simply Wall StCould The Rhythm Biosciences Limited (ASX:RHY) Ownership Structure Tell Us Something Useful?
2 months ago | Simply Wall StDid Changing Sentiment Drive Rhythm Biosciences's (ASX:RHY) Share Price Down A Worrying 52%?
Is Rhythm Biosciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RHY's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RHY's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RHY is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.
PE vs Market: RHY is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RHY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RHY is overvalued based on its PB Ratio (2.4x) compared to the AU Healthcare industry average (1.4x).
How is Rhythm Biosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Rhythm Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Rhythm Biosciences's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Rhythm Biosciences competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Rhythm Biosciences performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: RHY is currently unprofitable.
Growing Profit Margin: RHY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if RHY's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare RHY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RHY is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (4.3%).
Return on Equity
High ROE: RHY has a negative Return on Equity (-75.79%), as it is currently unprofitable.
How is Rhythm Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: RHY's short term assets (A$3.8M) exceed its short term liabilities (A$526.7K).
Long Term Liabilities: RHY's short term assets (A$3.8M) exceed its long term liabilities (A$20.5K).
Debt to Equity History and Analysis
Debt Level: RHY's debt to equity ratio (1.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if RHY's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RHY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RHY has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 50.5% each year.
What is Rhythm Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RHY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RHY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RHY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RHY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RHY's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Glenn Gilbert has been Chief Executive Officer of Rhythm Biosciences Ltd since November 28, 2018 and has been its Chief Operating Officer since May 21, 2018. Mr. Gilbert served as General Manager of Sa ...
CEO Compensation Analysis
Compensation vs Market: Glenn's total compensation ($USD260.61K) is about average for companies of similar size in the Australian market ($USD251.35K).
Compensation vs Earnings: Glenn's compensation has increased whilst the company is unprofitable.
|CEO & COO||1.5yrs||AU$391.93k||no data|
|Technical Director||1.5yrs||AU$331.18k||0.099% A$9.4k|
|Company Secretary||2.92yrs||AU$105.60k||11.02% A$1.0m|
|Joint Company Secretary||1.58yrs||no data||no data|
Experienced Management: RHY's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
|Technical Director||1.5yrs||AU$331.18k||0.099% A$9.4k|
|Non-Executive Director||2.75yrs||AU$42.00k||0.50% A$47.0k|
|Non-Executive Director||2.92yrs||AU$36.00k||0.53% A$49.8k|
|Chairman of the Board||0.58yr||no data||1.49% A$141.0k|
Experienced Board: RHY's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Rhythm Biosciences Limited's company bio, employee growth, exchange listings and data sources
- Name: Rhythm Biosciences Limited
- Ticker: RHY
- Exchange: ASX
- Founded: 2017
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: AU$9.471m
- Shares outstanding: 100.75m
- Website: https://www.rhythmbio.com
- Rhythm Biosciences Limited
- 500 Collins Street
- Level 17
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RHY||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Dec 2017|
|RHY||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Dec 2017|
Rhythm Biosciences Limited, a medical diagnostics technology company, engages in developing and commercializing medical diagnostics technology in Australia and internationally. It is developing ColoSTAT, a test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Melbourne, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/28 10:56|
|End of Day Share Price||2020/05/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.